1090 related articles for article (PubMed ID: 26097168)
1. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
2. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
3. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.
Galietta LJ
Paediatr Drugs; 2013 Oct; 15(5):393-402. PubMed ID: 23757197
[TBL] [Abstract][Full Text] [Related]
4. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
[TBL] [Abstract][Full Text] [Related]
5. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
7. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
8. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
9. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
10. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane regulator correctors and potentiators.
Rowe SM; Verkman AS
Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23818513
[TBL] [Abstract][Full Text] [Related]
12. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
14. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
[No Abstract] [Full Text] [Related]
15. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
16. Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules.
Baatallah N; Bitam S; Martin N; Servel N; Costes B; Mekki C; Chevalier B; Pranke I; Simonin J; Girodon E; Hoffmann B; Mornon JP; Callebaut I; Sermet-Gaudelus I; Fanen P; Edelman A; Hinzpeter A
Hum Mutat; 2018 Apr; 39(4):506-514. PubMed ID: 29271547
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
19. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
[TBL] [Abstract][Full Text] [Related]
20. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
